Table 1.
Baseline characteristics of participants in The Post-Transplant Glomerular Disease project with kidney failure due to IgA nephropathy and their kidney donors
| Baseline Characteristic | Overall Cohort (n=504) |
No Recurrence (n=422) |
Recurrence (n=82) |
| Follow-up, yrs | 8.7 (5.5–11.2) | 8.8 (5.5–11.3) | 8.2 (5.7–10.6) |
| Age at transplantation, yrs | 46 (37–55) | 46 (38–56) | 41 (32–54) |
| Age at diagnosis, yrs | 33 (26–44) | 34 (26–44) | 31 (25–41) |
| Male sex | 362 (72) | 302 (72) | 60 (73) |
| Race/Ethnicity | |||
| White | 354 (70) | 294 (70) | 60 (73) |
| Black | 13 (3) | 12 (3) | 1 (1) |
| Hispanic | 16 (3) | 14 (3) | 2 (2) |
| Asian | 33 (7) | 28 (7) | 5 (6) |
| Mixed | 5 (1) | 5 (1) | 0 (0) |
| Other/unknown | 83 (16) | 69 (16) | 14 (17) |
| BMI at transplantation, kg/m2 | 25.8±4.6 | 25.9±4.6 | 25.1±4.4 |
| Diseases associated with IgA nephropathy | |||
| Symptoms of Henoch-Schönlein purpura | 27 (5) | 23 (5) | 4 (5) |
| Autoimmune disease | 22 (4) | 18 (4) | 4 (5) |
| Liver disease | 7 (1) | 7 (2) | 0 (0) |
| Time from diagnosis to KF, mos | 66 (15–135) | 72 (17–143) | 48 (12–96) |
| Time on dialysis, mos | 17 (4–44) | 19 (5–44) | 11 (0–43) |
| Type of dialysis | |||
| Hemodialysis | 283 (56) | 239 (57) | 44 (54) |
| Peritoneal dialysis | 94 (19) | 87 (21) | 7 (9) |
| Both | 35 (7) | 29 (7) | 6 (7) |
| None (pre-emptive transplant) | 92 (18) | 67 (16) | 25 (30) |
| First degree family member with kidney disease | 11 (2) | 11 (3) | 0 (0) |
| Number of prior transplants | |||
| None | 434 (86) | 362 (86) | 72 (88) |
| 1 | 63 (13) | 55 (13) | 8 (10) |
| 2 | 7 (1) | 5 (1) | 2 (2) |
| PRA >50% | 35 (8) | 30 (8) | 5 (7) |
| DSA at time of transplant | 17 (4) | 11 (3) | 6 (8) |
| Deceased donor | 279 (56) | 238 (57) | 41 (51) |
| Extended criteria donor (KDPI>85%) | 48 (18) | 42 (19) | 6 (16) |
| Cold ischemia time, hours | 16±7 | 16±7 | 16±6 |
| Living donor | 222 (44) | 182 (43) | 40 (49) |
| Living related donor | 131 (60) | 107 (60) | 24 (62) |
| Donor age, years | 49 (39–58) | 50 (40–58) | 49 (35–57) |
| HLA-A/B/DR mismatch | 3.1±1.7 | 3.1±1.7 | 3.3±1.7 |
| Induction therapy | |||
| None | 74 (15) | 61 (15) | 13 (16) |
| Basiliximab | 203 (41) | 171 (41) | 32 (39) |
| Antithymocyte globulin | 176 (35) | 143 (34) | 33 (40) |
| Daclizumab | 39 (8) | 38 (9) | 1 (1) |
| Other | 8 (2) | 5 (1) | 3 (4) |
| Baseline immunosuppressive regimen | |||
| Tacrolimus + MMF + steroids | 355 (71) | 296 (70) | 59 (73) |
| Cyclosporine + MMF + steroids | 89 (18) | 77 (18) | 12 (15) |
| Tacrolimus + MMF | 19 (4) | 15 (4) | 4 (5) |
| Other | 40 (8) | 34 (8) | 6 (7) |
| Steroid free/ early steroid withdrawal | 76 (15) | 59 (14) | 17 (21) |
Values represent frequency (percentage), mean±SD or median (interquartile range). BMI, body mass index; KF kidney failure; PRA, panel reactive antibody; DSA, donor-specific antibody; KDPI, Kidney Donor Profile Index; MMF, mycophenolate mofetil.